Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00884052
Other study ID # Thrasher 02825-1
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date April 2007
Est. completion date October 2011

Study information

Verified date March 2020
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The hypothesis is that a loading dose of 20 mg/kg and a maintenance dose of 5 mg/kg of Levetiracetam is going to be safe and effective in the treatment of seizures in neonates.


Description:

In adults, drug clearance is less than half of the glomerular filtration rate and the drug half-life is 6-8 hours. Renal function in infants at birth is characterized by immature glomerular filtration and is only 20% that of older children. The specific esterase responsible for levetiracetam hydrolysis has not been identified and its expression in newborn infants is unknown. Depending on its activity, the expected infant total levetiracetam clearance will likely be between 15-45% of older populations. However, due to immaturity in levetiracetam clearance in infants, accumulation with multiple dosing is possible. Therefore the maintenance dose is reduced compared to older children according to the anticipated impaired clearance.

These anticipated differences in levetiracetam clearance and volume of distribution, will likely result in a prolonged drug half-life of 10-30 hours in infants. This prolonged elimination will require longer sampling to adequately characterize levetiracetam pharmacodynamics in this population.

The primary intent of the data analysis is to determine levetiracetam pharmacokinetics in newborn infants and predict the dosage necessary to maintain concentrations similar to those seen with effective therapy in other populations. Graphs of serum concentration vs. time will be plotted for levetiracetam for each infant. Mean serum drug concentration vs. time curves will also be constructed. Summary statistics (i.e., n, mean, standard deviation, minimum, maximum, and coefficient of variation) will be calculated for serum concentrations for each time point and each dose level.


Other known NCT identifiers
  • NCT00461409

Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date October 2011
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender All
Age group N/A to 14 Days
Eligibility Inclusion Criteria:

- Newborns admitted to the UCSD, Children's Hospital or Sharp Mary Birch NICUs with seizures.

- Term infants (gestational age greater than or equal to 37 weeks.

- > 2500 grams (max blood for study 6mL =3%).

- Postnatal age 14 days or less.

- Serum creatinine less than 1.2 at time of enrollment.

- Received loading dose of phenobarbital 20mg/kg.

- Are still experiencing either clinical or electroencephalographic seizures despite this therapy.

- For whom parental consent to participate in the study is obtained.

Exclusion Criteria:

- Biochemical abnormality - hypoglycemia, hypocalcemia-that when treated result in seizure cessation.

- Severe hypoxic ischemic injury likely to result in imminent death

- The only significant exclusions that will be made in recruitment and enrollment will be the exclusion of infants who are judged by the attending neonatologist to be so critically ill that death is imminent and benefit from neonatal intensive care is very unlikely.

- No rule-based criteria, (using lab or clinical parameters) adequately capture the complete nature of this clinical assessment.

- In general any child receiving active treatment with head cooling will not be excluded.

- Mechanical ventilation and/or the use of inotropic agents to support blood pressure will not be exclusion criteria.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Low dose levetiracetam
20 mg/kg loading dose; 5 mg/kg daily for 7 days.
High dose levetiracetam
40 mg/kg IV load; 10 mg/kg/day maintenance

Locations

Country Name City State
United States University of California, San Diego Medical Center / Neonatal Intensive Care Unit (NICU) San Diego California

Sponsors (2)

Lead Sponsor Collaborator
Richard H. Haas Thrasher Research Fund

Country where clinical trial is conducted

United States, 

References & Publications (1)

Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ, Haas RH. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res. 2012 Jul;72(1):43-9 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Drug Clearance Day 1 and Day 7
Primary Drug Half Life Day 1 and Day 7
Secondary Levetiracetam Treated Number of Participants With Serious Adverse Events 7 Days
See also
  Status Clinical Trial Phase
Recruiting NCT02850913 - Doxycycline for the Treatment of Nodding Syndrome Phase 2
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Not yet recruiting NCT06045676 - Electrocardiographic Changes Among Epileptic and Non Epileptic Seizures in Children at Sohag University Hospital
Completed NCT03722212 - Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT02897856 - Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures Phase 4
Completed NCT01239212 - Dosing of Levetiracetam (Keppra) in Neonates Phase 1/Phase 2
Completed NCT01236001 - Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older N/A
Completed NCT01703468 - Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions Phase 1
Completed NCT01702623 - Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions Phase 1
Recruiting NCT02216500 - Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy N/A
Completed NCT00236717 - A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy Phase 3
Terminated NCT03954314 - DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery Phase 3
Completed NCT05103735 - Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity
Terminated NCT03790436 - Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet N/A
Completed NCT06451289 - Study on Optic Nerve Sheath Diameter Measurements in Prolonged Pediatric Seizures
Recruiting NCT02552511 - Epidemiology Study on Neonatal Seizure
Recruiting NCT05339126 - RNS System LGS Feasibility Study Phase 2
Active, not recruiting NCT04595786 - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection N/A
Recruiting NCT04770337 - Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy N/A